Saturday, August 29, 2015

Stifel starts vTv Therapeutics at buy

Stifel starts vTv Therapeutics at buy

August 24, 2015 by · Leave a Comment 

Tweet Stifel has initiated coverage of vTv Therapeutics (NASDAQ:VTVT) with a “buy” rating and $17 price target, pointing to its significant Alzheimer’s disease (AD) and diabetes assets. The stock closed at $8.85 on Friday. “Unlike many of its predecessors, the company remained private and in stealth mode for two decades before going public with three […]

M Pharma advancing technologies for obesity and diabetes

M Pharma advancing technologies for obesity and diabetes

July 7, 2015 by · Leave a Comment 

Tweet M Pharmaceutical (OTCQB:MPHMF; CSE:MQ; FWB:T3F1.F) is advancing a family of biomedical technologies to manage obesity – TriMeo and TriMtec – and eMosquito to manage diabetes. “All three of our technologies represent a spectrum of solutions with reduced invasiveness and enhanced effectiveness than currently available approved solutions,” Dr. Martin Mintchev, president and CEO, says in […]

BioDelivery posts disappointing Clonidine trial results

BioDelivery posts disappointing Clonidine trial results

March 30, 2015 by · Leave a Comment 

Tweet Shares of BioDelivery Sciences International (NASDAQ:BDSI) lost more than a quarter of their market value at the mid-session on Monday after the company announced disappointing Phase 3 trial results with an experimental pain treatment under development. BioDelivery had tested its Clonidine topical gel as a treatment for diabetic neuropathy, a painful condition in which […]

Roth starts Cortendo AB at buy

Roth starts Cortendo AB at buy

February 27, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Cortendo AB (NOTC:CORT; OTC:CRTOF) with a “buy” rating and price target of $3. The stock closed at 97 cents on Thursday. Cortendo is conducting a global registration study with its lead asset COR-003, for the treatment of Cushing’s disease, which is caused by a corticotroph tumor of the […]

Tandem Diabetes in data partnership with Tidepool

Tandem Diabetes in data partnership with Tidepool

November 21, 2014 by · Leave a Comment 

Tweet Tandem Diabetes Care (NASDAQ:TNDM) has entered into a partnership with Tidepool, a non-profit dedicated to improving diabetes therapy management by offering an open source software platform that increases diabetes data accessibility. The accord will enable users of the Tidepool Platform, which is currently under development, to download and access data from Tandem’s t:slim Insulin […]

Tandem takes consumer device approach to insulin pumps

Tandem takes consumer device approach to insulin pumps

November 18, 2014 by · Leave a Comment 

http://www.youtube.com/watch?v=qMfQNC0MqbI&list=PLaVPFQzKqgRmCoJ4T6oNF7v3EWcnDCobu’]

Tweet Tandem Diabetes (NASDAQ:TNDM), which now markets the popular t:slim Insulin Pump for people with Type 1 diabetes and has two new pumps awaiting FDA clearance, has taken a unique consumer-focused approach to the design of its products. “When we started the company, we had to figure out why only 27% of people with Type […]

rEVO Biologics spearheading preeclampsia treatment

rEVO Biologics spearheading preeclampsia treatment

November 11, 2014 by · Leave a Comment 

Tweet Closely held rEVO Biologics is enrolling patients in a Phase 3 clinical trial of its ATryn recombinant human antithrombin for the treatment of early-onset preeclampsia, with top-line data expected in the second quarter of 2016. “This is a potentially life threatening disorder of pregnancy and a devastating unmet medical need,” Yann Echelard, president and […]

Stifel starts Vitae Pharma at buy

Stifel starts Vitae Pharma at buy

October 20, 2014 by · Leave a Comment 

Tweet Stifel has initiated coverage of Vitae Pharmaceuticals (NASDAQ:VTAE) with a “buy” rating and price target of $14. The stock closed at $6.30 on Friday. “Vitae’s unique technology platform encompasses the unique ability to rationally design clinical candidates and represents the principal competitive advantage of the company,” writes analyst Dr. Brian Klein. He said Vitae’s CONTOUR […]

Dipexium aims to have first topical antibiotic approved for DFI

Dipexium aims to have first topical antibiotic approved for DFI

September 2, 2014 by · Leave a Comment 

Tweet Dipexium (NASDAQ:DPRX) is enrolling patients in two pivotal Phase 3 trials of its Locilex topical antibiotic in what it hopes will be the first FDA-approved antibiotic topical cream for the treatment of mild infections of diabetic foot ulcers. “Current treatments used off-label to treat mild diabetic foot infections (DFI) generate systemic resistance, exhibit poor […]

WB starts Tandem Diabetes Care at outperform

WB starts Tandem Diabetes Care at outperform

July 15, 2014 by · Leave a Comment 

Tweet William Blair has initiated coverage of Tandem Diabetes Care (NASDAQ:TNDM) with an “outperform” rating and “aggressive growth” profile. The stock closed at $13.37 on Tuesday. Tandem Diabetes makes and markets a durable, tube-based insulin pump with an easy to train and use touch screen user interface to treat Type 1 and potentially Type 2 […]

Next Page »

Email Newsletters with Constant Contact
Google+